Compare SSRM & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | KRYS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | SSRM | KRYS |
|---|---|---|
| Price | $28.10 | $248.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $31.49 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 4.3M | 254.5K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $58.93 | $40.88 |
| Revenue Next Year | $6.60 | $35.16 |
| P/E Ratio | ★ $14.37 | $36.71 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $8.65 | $123.03 |
| 52 Week High | $33.49 | $298.30 |
| Indicator | SSRM | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 38.23 |
| Support Level | $27.80 | $233.64 |
| Resistance Level | $28.81 | $248.60 |
| Average True Range (ATR) | 1.73 | 9.14 |
| MACD | -0.45 | -2.19 |
| Stochastic Oscillator | 6.33 | 9.64 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.